All In Biotech

Drug Trial Radar · NCT06130722

First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study

First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FL115 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Dec 30, 2023

Primary completion

Feb 15, 2025

Study completion Sep 19, 2025

Sponsor

Sponsor type
Industry
First posted
Nov 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

First-in-Human, Phase I, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of FL115 in patients with advanced solid tumors who have progressed or are intolerant to current standard-of-care therapies, including immune check-point inhibitors administered in single-agent or combination use.

Conditions

  • Locally Advanced/Metastatic Solid Tumors

Interventions

  • FL115Drug

    FL115 is a novel long-acting IL-15 agonist designed as a fusion protein with a mutated IL-15 structure (IL-15\[N72D\]/IL-15Rα-sFc).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of FL115 in approximately 26 patients with unresectable locally advanced or metastatic solid tumorsTime frame: From screening to 30 days after last dose.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • HOAG Memorial Hospital Presbyterian

    Newport Beach, California

  • Moores Cancer Center at UCSD Health

    San Diego, California

  • Gabriel Cancer Center

    Canton, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.